Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

1 to 25 of 304 results

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

21-08-2014

The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment…

Boehringer IngelheimBrazilGenentechMexicoNovartisPfizerPharmaceuticalRespiratory and PulmonarySpirivaXolair

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

21-08-2014

UK pharma giant GlaxoSmithKline revealed late yesterday that the US Food and Drug Administration has…

Arnuity ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

15-08-2014

There was good news late yesterday for German family-owned pharma major Boehringer Ingelheim, when an…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivatiotropiumUS Food and Drug AdministrationUSA

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

ALK Abello reports strong improvement in 2nd-qtr financials

ALK Abello reports strong improvement in 2nd-qtr financials

13-08-2014

Denmark-based allergy specialist ALK Abello has reported significant progress in its sales for the second…

ALK AbelloDenmarkFinanceFinancialNorwegian kronePharmaceuticalRespiratory and Pulmonary

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

Vertex received European approval for CF drug Kalydeco

Vertex received European approval for CF drug Kalydeco

01-08-2014

US biotech firm Vertex Pharmaceuticals has announced that the European Commission has approved Kalydeco…

BiotechnologyCommittee for Medicinal Products for Human UseCystic fibrosisKalydecoPharmaceuticalRegulationRespiratory and PulmonaryUSAVertex Pharmaceuticals

FDA approves Boehringer’s Striverdi Respimat for COPD

FDA approves Boehringer’s Striverdi Respimat for COPD

01-08-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimPharmaceuticalPulmonologyRegulationRespiratory and PulmonaryStriverdi RespimatUSA

AstraZeneca to acquire Almirall’s respiratory franchise, for up to $2.1 billion

AstraZeneca to acquire Almirall’s respiratory franchise, for up to $2.1 billion

30-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement to gain rights to the respiratory franchise…

AlmirallAstraZenecaEkliraMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Stallergenes expands in Latin American with acquisition of Alergo Pharma

Stallergenes expands in Latin American with acquisition of Alergo Pharma

22-07-2014

French allergen specialist Stallergenes said this morning that it has acquired full ownership of Alergo…

Alergo PharmaAllergologyArgentinaImmunologyMedicineMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryStallergenes

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

GSK’s Anoro Ellipta approved in Japan for COPD

GSK’s Anoro Ellipta approved in Japan for COPD

04-07-2014

UK pharma giant GlaxoSmithKline and US partner Theravance said this morning that the Japanese Ministry…

Anoro ElliptaGlaxoSmithKlineJapanPharmaceuticalRespiratory and PulmonaryTheravance

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

30-06-2014

US pharma giant GlaxoSmithKline and US partner Theravance have submitted a supplemental New Drug Application…

Breo ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUSA

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Stallergenes publishes review of grass pollen tablet confirming efficacy

Stallergenes publishes review of grass pollen tablet confirming efficacy

24-06-2014

French allergen specialist Stallergenes has released comprehensive new data on the 5-grass pollen immunotherapy…

FrancePharmaceuticalResearchRespiratory and PulmonaryStallergenes

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

23-06-2014

UK-based biotechnology company Verona Pharma says that the Phase IIa clinical trial to evaluate the efficacy…

PharmaceuticalResearchRespiratory and PulmonaryUKVerona Pharma

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

16-06-2014

Denmark-based allergy specialist ALK Abello partner for Japan, Torii Pharmaceutical, has completed its…

ALK AbelloJapanPharmaceuticalRegulationResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

1 to 25 of 304 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top